Sort by
Refine Your Search
-
Listed
-
Program
-
Employer
- University of Oxford
- AALTO UNIVERSITY
- Nature Careers
- UNIVERSITY OF SURREY
- King's College London
- Manchester Metropolitan University
- Queen Mary University of London;
- SINGAPORE INSTITUTE OF TECHNOLOGY (SIT)
- UCL;
- University of Hull;
- University of Oxford;
- University of Portsmouth;
- University of Surrey
- 3 more »
- « less
-
Field
-
works closely with national and international leading academic institutes and key industrial partners. In November 2020, 6GIC was officially launched with parallel research undertaken in both 5G+ and 6G
-
molecular biology and genetics, and experience with DNA-binding proteins are beneficial. They will use structural and biochemical approaches to determine how Exo7 recognises and processes DNA-protein
-
works closely with national and international leading academic institutes and key industrial partners. In November 2020, 6GIC was officially launched with parallel research undertaken in both 5G+ and 6G
-
launched with parallel research undertaken in both 5G+ and 6G for 2030+. About you Applicants should have a good honors PhD degree in wireless communications or AI and computer vision fields and a strong
-
how Exo7 recognises and processes DNA-protein crosslinks and how this pathway contributes to bacterial survival following antibiotic treatment. This work will be tightly coordinated with live-cell
-
separate technologies but can now, due to advances in digital processing and system integration, be deployed jointly on common hardware platforms. This convergence opens up a new and growing research domain
-
the group can test and validate models of sodium-ion battery behaviour. As such, proficiency in computer programming (particularly python) is required as well as knowledge of numerical methods
-
keeping. Strong organisational skills, with the ability to plan and prioritise tasks across parallel activities (e.g., sample processing, biobanking, and experimental support) and meet deadlines as
-
following treatment. NEWDAY-ABC is a hybrid intervention-implementation trial that will be carried out at four sites across Yorkshire and Greater Manchester. The parallel process evaluation will assess
-
neuroplasticity, interdisciplinary neuro-immune research, high-throughput sequencing technologies, drug discovery and advanced therapeutics. We have excellent facilities to support our parallel use of pre-clinical